Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea

References

• WHO. Influenza. Geneva (Switzerland): WHO. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/influenza.
   Google Scholar
• (WHO) WHO. Influenza (Seasonal); 2023. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
   Google Scholar
• Yun JW, Choi MJ, Shin GS, Lim JO, Noh JY, Kim YK, Song JY, Kim WJ, Choi S-E, Cheong HJ, et al. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. PLOS ONE. 2019;14(1):e0209643. doi:10.1371/journal.pone.0209643.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–9. doi:10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Park M, Wu P, Goldstein E, Joo Kim W, Cowling BJ. Influenza-associated excess mortality in South Korea. Am J Prev Med. 2016;50:111–119. doi:10.1016/j.amepre.2015.09.028.
   PubMedGoogle Scholar
• Seo J, Lim J. The impact of free vaccination policies under the Korean influenza national immunization program: trends in influenza vaccination rates in South Korea from 2010 to 2019. PLOS ONE. 2022;17(1):e0262594. doi:10.1371/journal.pone.0262594.
   Web of Science ®Google Scholar
• Kim J, Dorgan JF, Kim H, Kwon O, Kim Y, Kim Y, Ko KS, Park YJ, Park H, Jung S. Association between use of nutrition labels and risk of chronic kidney disease: the Korean National Health and Nutrition Examination Survey (KNHANES) 2008–2019. Nutrients. 2022 Apr 21;14(9):1731. doi:10.3390/nu14091731.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, Lu M, Pratt D, Chu S, Wernecke M, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017–2018. J Infect Dis. 2018;220:1255–1264. doi:10.1093/infdis/jiy716.
   Web of Science ®Google Scholar
• Morse K, Cleveland KW. Efficacy of the adjuvanted influenza vaccine compared with the high-dose for older people. Sr Care Pharm. 2023;38(4):156–160. doi:10.4140/TCP.n.2023.156.
   PubMedGoogle Scholar
• Seqirus C. CSL seqirus products. www.csl.com.
   Google Scholar
• Dae-Yeol N. CSL seqirus “Immune-boosting quadrivalent flu vaccine for the elderly, approved in Korea”. Hit News; 2022. http://www.hitnews.co.kr/news/articleView.html?idxno=41557.
   Google Scholar
• KSID. 2023 adult immunization recommendations. Influenza vaccine; 2023. www.ksid.or.kr.
   Google Scholar
• Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccines Immunother. 2018;14(3):550–564. doi:10.1080/21645515.2017.1415684.
   PubMed Web of Science ®Google Scholar
• Boikos C, Fischer L, O’Brien D, Vasey J, Sylvester GC, Mansi JA. Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults >/= 65 years during the 2017–2018 and 2018–2019 influenza seasons. Clin Infect Dis. 2021;73(5):816–823. doi:10.1093/cid/ciab152.
   PubMed Web of Science ®Google Scholar
• Ruiz-Aragon J, Marquez-Pelaez S, Gani R, Alvarez P, Guerrero-Luduena R. Cost-effectiveness and burden of disease for adjuvanted quadrivalent influenza vaccines compared to high-dose quadrivalent influenza vaccines in elderly patients in Spain. Vaccines. 2022;10(2):176. doi:10.3390/vaccines10020176.
   Web of Science ®Google Scholar
• Fochesato A, Sottile S, Pugliese A, Márquez-Peláez S, Toro-Diaz H, Gani R, Alvarez P, Ruiz-Aragón J. An economic evaluation of the adjuvanted quadrivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine in the Spanish older adult population. Vaccines. 2022;10(8):1360. doi:10.3390/vaccines10081360.
   Web of Science ®Google Scholar
• Marbaix S, Dauby N, Mould-Quevedo J. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population. Expert Rev Vaccines. 2023;22(1):608–619. doi:10.1080/14760584.2023.2229917.
   Web of Science ®Google Scholar
• Choi MJ, Yun JW, Song JY, Ko K, Mould JF, Cheong HJ. A comparative analysis of influenza-associated disease burden with different influenza vaccination strategies for the elderly population in South Korea. Vaccines. 2022;10(9):1387. doi:10.3390/vaccines10091387.
   Web of Science ®Google Scholar
• Han-Joo K. Seqirus eyes swift introduction of influenza vaccines into S.Korea. Seoul (Korea): Yonhap News Agency; 2022. https://en.yna.co.kr/view/AEN20220216008100320?section=search.
   Google Scholar
• KDCA. Status of national influenza vaccination support project for the 2018–2019 season. In: Department V, editor; 2019. www.kdca.go.kr.
   Google Scholar
• Hwang SH, Lee H, Jung M, Kim SH, Sung HK, Oh MD, Lee JY. Incidence, severity, and mortality of influenza during 2010–2020 in Korea: a nationwide study based on the population-based national health insurance service database. J Korean Med Sci. 2023;38(8). doi:10.3346/jkms.2023.38.e58.
   Web of Science ®Google Scholar
• KDCA. Annual influenza vaccination rate. www.chs.kdca.go.kr.
   Google Scholar
• Nguyen VH, Ashraf M, Mould-Quevedo JF. Cost-effectiveness of the use of adjuvanted quadrivalent seasonal influenza vaccine in older adults in Ireland. Vaccines. 2023;11(5):933. doi:10.3390/vaccines11050933.
   Web of Science ®Google Scholar
• Longini IM Jr., Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159(7):623–633. doi:10.1093/aje/kwh092.
   PubMed Web of Science ®Google Scholar
• Bolge SC, Kariburyo F, Yuce H, Fleischhackl R. Predictors and outcomes of hospitalization for influenza: real-world evidence from the United States medicare population. Infec Dis Ther. 2021;10(1):213–228. doi:10.1007/s40121-020-00354-x.
   PubMed Web of Science ®Google Scholar
• Galvani AP, Reluga TC, Chapman GB. Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci. 2007;104(13):5692–5697. doi:10.1073/pnas.0606774104.
   PubMed Web of Science ®Google Scholar
• Hong TH, Lee HS, Kim NE, Lee KJ, Kim YK, An JN, Kim J-H, Kim HW, Park S. Recent increases in influenza-related hospitalizations, critical care resource use, and In-hospital mortality: a 10-year population-based study in South Korea. J Clin Med. 2022;11(16):4911. doi:10.3390/jcm11164911.
   PubMed Web of Science ®Google Scholar
• KDCA. Guidelines for the management of the NIP for influenza in the 2023–2024 season; 2023. https://nip.kdca.go.kr/irhp/infm/goRefcBrdView.do.
   Google Scholar
• Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013;31(50):6030–6033. doi:10.1016/j.vaccine.2013.09.063.
   PubMed Web of Science ®Google Scholar
• Coleman BL, Sanderson R, Haag M, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15:813–823. doi:10.22541/au.161933909.92394260/v1.
   PubMed Web of Science ®Google Scholar
• Shin G, Kang D, Cheong HJ, Choi SE. Cost-effectiveness of extending the national influenza vaccination program in South Korea: does vaccination of older adults provide health benefits to the entire population? Vaccines. 2022;10(6):932. doi:10.3390/vaccines10060932.
   Google Scholar
• Wu DBC, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Smith PF, Kirkpatrick CM, Kamal MA, Nieforth K, et al. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach – linking pharmacology, epidemiology and heath economics. Epidemiol Infec. 2018;146(4):496–507. doi:10.1017/S0950268818000158.
   PubMed Web of Science ®Google Scholar
• Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza a (H5N1) pandemic. Ann Intern Med. 2009;151(12):840. doi:10.7326/0000605-200912150-00156.
   PubMed Web of Science ®Google Scholar
• Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine. 2006;24(7):1035–1043. doi:10.1016/j.vaccine.2004.12.033.
   PubMed Web of Science ®Google Scholar
• Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, Dremsizov TT, Pinsky MR. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(6):1389–1394. doi:10.1164/ajrccm.163.6.2005123.
   PubMed Web of Science ®Google Scholar
• Macario A, Chow JL, Dexter F. A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome. BMC Med Inform Decis Mak. 2006;6(1):15. doi:10.1186/1472-6947-6-15.
   PubMedGoogle Scholar
• WHO. The global health observatory; 2020. www.who.int.
   Google Scholar
• KOSIS. Population census(sex- and age-specific). Seoul (Korea): KOSIS; 2021. https://gsis.kwdi.re.kr/statHtml/statHtml.do?orgId=338&tblId=DT_1IN0503&conn_path=I2.
   Google Scholar
• KDCA. North Chungcheong Province (South Korea). 2023. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&act=view&list_no=722739#.
   Google Scholar
• KDCA. North Chungcheong Province (South Korea). 2023. https://www.kdca.go.kr/board/board.es?mid=a20505010000&bid=0017&act=view&list_no=721582.
   Google Scholar
• Baltussen RM, Adam T, Tan-Torres Edejer T, World Health O. Making choices in health - WHO guide to cost effectiveness analysis: WHO guide to cost-effectiveness analysis. Vol. 78. Albany: World Health Organization Albany; 2004. doi:10.1590/s1135-57272004000300012.
   Google Scholar
• Bank TW. GDP per capita (current US$) - Korea, Rep. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=KR.
   Google Scholar
• Ruiz-Aragón J, Márquez-Peláez S, Gani R, Alvarez P, Guerrero-Luduena R. Cost-effectiveness and burden of disease for adjuvanted quadrivalent influenza vaccines compared to high-dose quadrivalent influenza vaccines in elderly patients in Spain. Vaccines. 2022;10(2):176. doi:10.3390/vaccines10020176.
   Web of Science ®Google Scholar
• Calabrò GE, Boccalini S, Panatto D, Rizzo C, Di Pietro ML, Abreha FM, Ajelli M, Amicizia D, Bechini A, Giacchetta I, et al. The new quadrivalent adjuvanted influenza vaccine for the Italian elderly: a health technology assessment. Int J Environ Res Public Health. 2022;19(7):4166. doi:10.3390/ijerph19074166.
   PubMed Web of Science ®Google Scholar
• Kohli MA, Maschio M, Mould-Quevedo JF, Drummond M, Weinstein MC. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom. Hum Vaccin Immunother. 2021;17(11):4603–4610. doi:10.1080/21645515.2021.1971017.
   PubMed Web of Science ®Google Scholar
• Kohli MA, Maschio M, Cartier S, Mould-Quevedo J, Fricke FU. The cost-effectiveness of vaccination of older adults with an MF59-adjuvanted quadrivalent influenza vaccine compared to other available quadrivalent vaccines in Germany. Vaccines. 2022;10(9):1386. doi:10.3390/vaccines10091386.
   Web of Science ®Google Scholar